The Life Sciences team advised SpringWorks Therapeutics on its global clinical collaboration with BeiGene to evaluate the safety, tolerability and preliminary efficacy of combining BeiGene’s investigational RAF dimer inhibitor, lifirafenib (BGB-283) and SpringWorks Therapeutics’ investigational MEK inhibitor, PD-0325901, in patients with advanced solid tumors. Under the terms of the agreement, BeiGene will be responsible for administering the Phase 1b clinical trial, with all costs of the clinical studies and governance responsibilities to be shared equally among both parties. SpringWorks Therapeutics will also oversee fixed-dose formulation work as part of the collaboration.
SpringWorks Therapeutics is a clinical-stage rare disease and oncology company focused on sourcing and developing innovative treatments for underserved patient populations.
The Goodwin team was led by partner Kingsley Taft.
For additional details on the collaboration, please read the press release.